Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Jasper Therapeutics, Inc. Common Stock

Jasper Therapeutics is a biotechnology company on a mission to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, and safer and more effective conditioning for monogenetic diseases.

Abingworth

Alexandria Venture Investments

Amgen

Apeiron Investment Group

Avego Healthcare Capital

Roche Venture Fund

Kingdon Capital

Woodline Partners

Federated Kaufmann Fund

Velan Capital

Qiming Venture Partners USA

Citadel

TSVC

Surveyor Capital

Jasper Therapeutics

Today, Jasper provided a recap its recent accomplishments, including the authorization by the European Medicines Agency of the Company’s Clinical Trial Applications for its Phase 1b/2a BEACON study of briquilimab in CSU and Phase 1b/2a SPOTLIGHT study in CIndU. Read the full announcement here: https://lnkd.in/gcDX6niJ

Results from two studies evaluating briquilimab as a conditioning agent for stem cell transplant were presented at the American Society of Hematology 2023 annual meeting. Read a summary of the results presented here: https://lnkd.in/gJ4GFQGU

Fascinating paper which concluded: A large proportion of CSU patients treated with H1AH-based therapies had uncontrolled disease, contributing to increased HRU and patient burden. Non-responders had more comorbidities and HRU at baseline and follow-up, with steep increases in follow-up hospitalizations relative to baseline, highlighting an urgent need for early disease control.  
At Jasper we are seeking to address this high unmet need. #Jaspertherapeutics

Jasper is pleased to announce that the first patient has been dosed in the Phase 1b/2a BEACON study evaluating briquilimab in CSU

Read the full announcement here: https://lnkd.in/gX4DNe7h

The Jasper team wishes everyone a restful and joyful Thanksgiving holiday!

Jasper is excited to participate in the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Meeting. Tomorrow at 3:45pm PT Charles C. will be presenting preclinical data demonstrating that briquilimab prevents passive systemic anaphylaxis in mice expressing chimeric human/mouse CD117 during the “Meet the Authors” poster session in Exhibition Hall C (Level 1). View the poster here: https://lnkd.in/gc9aQ5Es

CSU affects 40 million people worldwide, and around 60% need an option beyond standard-of-care antihistamines, according to Novartis.  As a clinician, it is exciting to see potential new medicines coming into clinic for patients with high unaddressed needs.

https://lnkd.in/g9-qEBKj

Jasper is pleased to report third quarter 2023 financial results. Read the full announcement here: https://lnkd.in/greDRAD4

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023.

Read the full announcement here: https://lnkd.in/dsf4EK7S

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-4.99K -	-31.67M 634,931.08%	-30.64M 3.26%	-37.69M 23.00%	-64.47M 71.06%
depreciation and amortization		21K -	377K 1,695.24%	975K 158.62%	1.11M 13.64%
deferred income tax		-21K -	3.00M 14,390.48%		-4.38M -
stock based compensation	6 -	1.21M 20,166,566.67%	1.05M 13.39%	4.09M 290.36%	5.21M 27.38%
change in working capital		1.30M -	1.62M 25.08%	-649K 140.04%	5.10M 886.29%
accounts receivables			600K -	-663K 210.50%	663K 200%
inventory			-600K -	663K 210.50%
accounts payables		358K -	2.94M 720.67%	-2.15M 173.21%	2.38M 210.69%
other working capital		938K -	-1.32M 240.41%	1.50M 214.05%	2.06M 37.08%
other non cash items	3.01K -	10.90M 361,652.99%	-9.09M 183.41%	-12.59M 38.53%	5.36M 142.57%
net cash provided by operating activities	-1.97K -	-18.27M 927,629.81%	-33.68M 84.37%	-45.86M 36.17%	-52.07M 13.54%
investments in property plant and equipment			-2.43M -	-576K 76.28%	-267K 53.65%
acquisitions net
purchases of investments
sales maturities of investments
other investing activites		198.34K -
net cash used for investing activites		198.34K -	-2.43M 1,324.14%	-576K 76.28%	-267K 53.65%
debt repayment
common stock issued		11.29M -	10.75M 4.76%	27K 99.75%	101.93M 377,422.22%
common stock repurchased				28K -	64K 128.57%
dividends paid
other financing activites	29.13K -	11.29K 61.25%	90.22M 799,217.80%		-1.02M -
net cash used provided by financing activities	29.13K -	11.29M 38,649.66%	100.97M 794.56%	55K 99.95%	100.97M 183,483.64%
effect of forex changes on cash		-198.34K -
net change in cash	27.16K -	-6.98M 25,800.50%	64.86M 1,029.27%	-46.38M 171.50%	48.64M 204.87%
cash at beginning of period	4 -	27.16M 679,074,900%	20.18M 25.70%	85.05M 321.37%	38.25M 55.02%
cash at end of period	27.16K -	20.18M 74,203.28%	85.05M 321.37%	38.67M 54.53%	86.89M 124.71%
operating cash flow	-1.97K -	-18.27M 927,629.81%	-33.68M 84.37%	-45.86M 36.17%	-52.07M 13.54%
capital expenditure			-2.43M -	-576K 76.28%	-267K 53.65%
free cash flow	-1.97K -	-18.27M 927,629.81%	-36.11M 97.66%	-46.43M 28.60%	-52.33M 12.71%

NASDAQ:JSPR

Jasper Therapeutics

Last Close

21.26

26/07 20:00

Market Cap

310.61M

Beta: 1.99

Volume Today

193.96K

Avg: 1.11M

PE Ratio

−22.01

PFCF: −2.88

Preview